^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLN-978

    i
    Other names: CLN-978
    Company:
    Cullinan Therap
    Drug class:
    CD3 agonist, CD19 inhibitor
    Related drugs:
    2d
    CLN-978-SJ-101: A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogrens Disease (2025-521462-96-00)
    P1, N=30, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    12d
    CLN-978-SL-101: A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) (2024-518780-36-00)
    P1, N=8, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978
    17d
    CLN-978-SL-101: A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) (2024-518780-36-00)
    P1, N=8, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    8ms
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease (clinicaltrials.gov)
    P1, N=36, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    9ms
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=37, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978
    9ms
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=37, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    1year
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=24, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978
    over1year
    A Study of CLN-978, a CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    almost2years
    A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLN-978
    over2years
    A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) (ASH 2023)
    Approximately 90 patients (30 in dose escalation and 60 in dose expansion) will be enrolled at approximately 6 sites in the U.S., reflecting both community and academic centers. The study is currently enrolling (NCT05879744).
    Clinical • P1 data
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    CLN-978
    over2years
    CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. (PubMed, J Immunother Cancer)
    CLN-978 warrants further exploration. An ongoing clinical phase 1 trial is investigating safety, pharmacokinetics, pharmacodynamics, and the initial therapeutic potential of subcutaneously administered CLN-978 in patients with non-Hodgkin's lymphoma.
    Journal
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD19 underexpression
    |
    CLN-978